BioTuesdays

Tag - Cantor Fitzgerald

NexImmune-Logo

Cantor starts NexImmune at OW, PT $35

Cantor Fitzgerald launched coverage of NexImmune (NASDAQ:NEXI) with an “overweight” rating and price target of $35. The stock closed at $20.63 on March 8. NexImmune is developing a novel approach in cancer immunotherapy...

Akebia-Therapeutics-Logo

Cantor starts Akebia Therapeutics at OW; PT $8

Cantor Fitzgerald launched coverage of Akebia Therapeutics (NASDAQ:AKBA) with an “overweight” rating and $8 price target. The stock closed at $3.41 on March 5. The company’s lead asset, vadadustat, is an oral hypoxia...

Heat Biologics

Cantor starts Heat Biologics at OW; PT $22

Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...

Cantor starts DarioHealth at OW; PT $35

Cantor Fitzgerald launched coverage of DarioHealth (NASDAQ:DRIO) with an “overweight” rating and price target of $35. The stock closed at $29.16 on Feb. 24. Dario is a digital health company that is developing and...

Cantor cuts Otonomy PT to $6 from $13

Cantor Fitzgerald slashed its price target for Otonomy (NASDAQ:OTIC) to $6 from $13 but maintained its “overweight” rating, after the company announced that the Phase 3 study of OTIVIDEX in Ménière’s disease did not...

Evolus

Cantor ups Evolus PT to $20 from $11

Cantor Fitzgerald raised its price target for Evolus (NASDAQ:EOLS) to $20 from $11, following a litigation settlement, which Cantor believes “increases earnings visibility for Evolus, and removes a large overhang on the...

iBio Inc. Logo

Cantor Fitzgerald starts iBio at OW; PT $3

Cantor Fitzgerald launched coverage of iBio (NYSE American:IBIO) with an “overweight” rating and price target of $3. The stock closed at $1.46 on Jan. 21. iBio focuses on plant-made biologics manufacturing, which is...